Drug-eluting versus nondrug peripheral vascular interventions.

INTRODUCTION

Drug-eluting (DRUG) peripheral vascular interventions (PVIs) are associated with higher patency rates than nondrug (NONDRUG) PVIs. Recent data raised safety concerns with using DRUG devices in PVIs.

MATERIAL AND METHODS

The study population was extracted from the 2016 Nationwide Readmissions Database using the International Classification of Diseases, tenth edition, clinical modifications/procedure coding system codes for PVI, DRUG and NONDRUG devices, and in-hospital procedural complications. Study endpoints included in-hospital all-cause mortality, length of index hospitalization, acute kidney injury (AKI), amputation, compartment syndrome, vascular complications, bleeding, and blood transfusion. Propensity matching was used to adjust for baseline characteristics.

RESULTS

49,883 discharged patients who underwent lower extremity arterial PVI were identified, 25.3% DRUG and 74.7% NONDRUG PVI. Mean age was 68.3 years and 40.6% were female. Critical limb ischemia was reported in 33.2%, claudication in 7.6%, and acute limb ischemia in 0.1%. In comparison to the NONDRUG group, the DRUG group was associated with lower in-hospital all-cause mortality (2.2 vs. 2.9%, < 0.001), shorter length of index hospitalization (8.3 vs. 8.6 days, = 0.001), bleeding (12.0% vs. 13.5%, < 0.001), and need for blood transfusion (10.1% vs. 11.0%, = 0.004). There was no significant difference in terms of AKI (17.3% vs. 18.0%, = 0.10), amputation (15.3% vs. 15.4%, = 0.63), compartment syndrome (0.5% vs. 0.6%, = 0.07), or vascular complications (0.8% vs. 0.8%, = 0.50). After propensity matching, the mortality benefit was no longer present.

CONCLUSIONS

DRUG PVI was associated with lower in-hospital all-cause mortality, bleeding events and shorter length of index hospitalization and comparable vascular-related complications. However, this mortality benefit was no longer present after propensity matching.